Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Last trade$51.81
Day change+$0.24 (+0.47%)
Day range$50.78 – $52.09
Volume2,241,171
Market cap$31.80B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for GMAB.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for GMAB.
Recent news
Company coverage with links to the original publishers.
First Trust's FBT and Invesco's PBE are compared as primary vehicles for biotech sector exposure. FBT offers lower fees (0.55% vs 0.59%), higher AUM ($3.0B vs $438M), and stronger 1-year returns (35.7% vs 28.1%), while PBE provides dividend income and uses a multi-factor quantitative approach. The choice depends on investor priorities regarding cost, liquidity, and investment strategy.
Genmab A/S announced the disclosure of share transactions by managerial employees and their closely associated persons in accordance with market abuse regulations. The company also announced a capital increase of 164,828 shares resulting from employee warrant exercises.
Genmab announced that 22 abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody, will be presented at the 2026 ASH Annual Meeting in December. Highlights include first presentation of Phase 3 EPCORE DLBCL-4 study results showing epcoritamab plus lenalidomide in relapsed/refractory DLBCL, along with updated data from multiple trials across B-cell malignancies demonstrating the drug's versatility as monotherapy and in combinations.
Incyte Corporation and Genmab A/S have entered into a clinical trial collaboration to evaluate a combination therapy for first-line treatment of metastatic colorectal cancer (mCRC) with KRAS G12D mutations. The combination includes Incyte's INCB161734 (KRAS G12D inhibitor), Genmab's petosemtamab (bispecific antibody), and standard chemotherapy. Genmab will lead the phase I/II study while Incyte provides the drug and shares development costs.
Genmab announced updated Phase 2 trial results for petosemtamab, a bispecific antibody targeting EGFR and LGR5, showing encouraging objective response rates of 75% in first-line and 67% in second-line metastatic colorectal cancer patients when combined with standard chemotherapy. The data demonstrates durable responses and supports the ongoing global Phase 3 development program.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.